Supply Update

Mylan is experiencing intermittent disruptions in the supply of Hiprex 1mg tablets due to an increase in demand above the normal levels of supply. We are working closely with the manufacturer to manage future stock deliveries so that we achieve a steady state of supply.

In the meantime, this has resulted in normal stock levels not always being available.

With access to medicine a priority, we would like to assure patients that we are doing everything we can to resolve this situation as quickly as possible and only anticipate the current supply issue to continue temporarily.

Information for Patients


Mylan is unable to make any specific treatment recommendations to patients and recommend that patients speak to their healthcare provider to discuss treatment options according to their own health needs and their relevant clinical history.

Reporting of side effects

If you experience any side effects please talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at http://www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine. You should also report any side effects to Mylan UK Pharmacovigilance on +44 (0)800 121 8267 or ukpharmacovigilance@mylan.com.

About Hiprex


Hiprex is indicated in the prophylaxis and treatment of urinary tract infections.

Resources


Hiprex SmPC (summary of product characteristics) Hiprex Patient Information Leaflet

Contact Information


Mylan Medical Information team can be contacted via the Mylan switch board on 01707 853000



HIP-2019-0002
DOP: JUNE 2019